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ABSTRACT 
Based upon the known potential interaction between omeprazole (OMP) and clopidogrel (CLOP), the current study 
was designed to evaluate the effect of CLOP on disposition of OMP and its two major metabolites, 5-hy-
droxyomeprazole (5-OH-OMP) and omeprazole sulfone (OMP-S) in healthy clinical subjects. A randomized, open 
label, 2-period, crossover study was designed. Twelve volunteers were selected, of whom eight were extensive 
metabolizers (EM) of CYP2C19 and 4 were poor metabolizers (PM). They received single dose of OMP either 
alone or in combination with CLOP (single dose) and samples were collected periodically to calculate various 
pharmacokinetic parameters. Changes in most of the pharmacokinetic parameters of OMP, 5-OH-OMP and OMP-
S were insignificant (P ˃ 0.05) both in EM and PM except for the maximum concentration (Cmax) of 5-OH-OMP 
and OMP-S in EM. The OMP Cmax and AUC0-∞ was increased both in EM and PM after concomitant administration 
of OMP with CLOP. The 5-OH-OMP Cmax was decreased in both EM and PM, demonstrating that CLOP inhibits 
hydroxylation of OMP. The OMP-S Cmax and AUC0-∞ were increased both in EM and PM showing that CLOP 
may induce sulfoxidation of OMP. It was concluded that CLOP may inhibit hydroxylation of OMP to a greater 
extent in EM than in PM, leading to higher OMP Cmax and AUC0-∞. Furthermore, the sulfoxidation of OMP may 
also be induced by CLOP. So, it is suggested that both these drugs should be carefully prescribed together to avoid 
any harm to the patients. (Application number13/EC/Pharm. Ref number 12/Pharm). 
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INTRODUCTION 
Proton pump inhibitors (PPIs) are the 
most widely prescribed drugs for gastrointes-
tinal tract (GIT) problems and the second 
most prescribed drug worldwide (Vanderhoff 
and Tahboub, 2002). On the basis of their 
safety and efficacy they are prescribed exces-
sively both in, ambulatory and admitted pa-
tients.  PPIs include: omeprazole (OMP), pan-
toprazole, lansoprazole, rabeprazole, 
esomeprazole, tenatoprazole and timoprazole. 
Clinical studies have shown that PPIs are safe, 
effective and well tolerated (Reilly, 1999). 
PPIs perform their antisecretory action by 
inhibiting the proton pump, i.e., H+/K+ 
ATPase (adenosine triphosphatase) after con-
version into its active form. These drugs un-
dergo structural modification in the canalicu-
lus in the presence of high acid content. More 
precisely, in the acidic environment, a PPI is 
converted from pro-drug to active form i.e., 
sulphenamide, which inhibits the acidic secre-
tion by irreversibly binding to the proton 
pump (Stedman and Barclay, 2000). 
OMP is extensively metabolised in the 
liver. The two major metabolites of OMP are 
5-hydroxy omeprazole (5-OH-OMP) (Chiba 
et al., 1993) and omeprazole sulphone (OMP-
S) (Andersson et al., 1993). OMP is metabo-
lised to thesetwo metabolites by CYP2C19 
and CYP3A4, respectively. Both 5-OH-OMP 
and OMP-S are inactive and do not exhibitany 
pharmacodynamic effect (Meyer, 1996).  
CLOP is an oral antiplatelet agent, be-
longing to the thienopyridine class. It inhibits 
clot formation in the blood in various diseases 
like peripheral vascular disease, coronary ar-
tery disease and cerebrovascular disease (Ku-
bler et al., 2004).The oral bioavailability of 
CLOP is less than 50 %. Absorption of CLOP 
is unaffected by food or antacids (McEwen et 
al., 1999). Evidence is there to suggest that 
CLOP is metabolized by CYP2C19 (Fontana 
et al., 2007) and CYP3A4 (Lau et al., 2004) 
to its active metabolite. 
There have been reports of drug-drug in-
teraction between CLOP and PPIs. OMP di-
minishes CLOP effect, thus posing a threat to 
the patient (Norgad et al., 2009; Gupta et al., 
2010; Kreutz et al., 2010). The European and 
United States regulatory authorities in 2009 
and 2010 warned against the concomitant use 
of OMP with CLOP (Angiolillo et al., 2011). 
However, even after these recommendations 
co-administration of OMP with CLOP is still 
practiced posing threat to patients’ health 
(Berger, 2015). Likewise, OMP pharmacoki-
netics has also been evaluated previously 
showing that OMP levels are raised by lower-
ing its metabolism through inhibition of 
CYP2C19 (Chen et al., 2009). Considering 
these findings, this study was designed to 
evaluate the pharmacokinetics of OMP and its 
metabolites in presence of CLOP in both EM 
and PM of CYP2C19. 
 
METHODOLOGY 
Subjects 
A group of twelve healthy volunteers 
were recruited for this study (divided into two 
groups), and written informed consent was 
obtained from all participants included in the 
study. The ages of the volunteers were in the 
range of 23-29 years. The body mass index 
was 23.22 ± 1.16 lb/in2. Electrocardiogram, 
routine lab tests including hematological, kid-
ney and liver function tests were performed 
for all the volunteers. They were physically 
examined and their medical history was also 
evaluated. All volunteers were non-smokers 
and abstained from taking any other medicine 
and juices in the week prior to the study. Vol-
unteers were served standard breakfast and 
lunch during the study. Volunteers were di-
vided into extensive metabolizers (n = 8) and 
poor metabolizers (n = 4) of CYP2C19 on the 
basis of drug-metabolite ratio (OMP: 5-OH-
OMP). 
 
Study design 
This study was conducted in accordance 
to “World Medical Association (WMA) dec-
laration of Helsinki−Ethical principles for 
medical research involving human subjects” 
and its amendments. The study was approved 
by the ethical committee, Department of 
Pharmacy, University of Peshawar, Pakistan. 
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(Application number13/EC/Pharm. Ref num-
ber 12/Pharm). It was a single dose, 2-period, 
2-sequence study with 14 days washout pe-
riod. OMP (Omega 40 mg, Ferozsons Labs 
Pvt., Ltd., Nowshehra, Pakistan) was either 
administered alone or in combination with 
CLOP (Clopid 150 mg, Ferozsons Labs Pvt., 
Ltd., Nowshehra, Pakistan) as shown in Table 
1. 
 
Analytical method and pharmacokinetic 
analysis 
Approximately 3 mL of blood was col-
lected from each volunteer at 0, 0.5, 1, 2, 3, 4, 
6, and 8 hr after dose administration in hepa-
rinized tubes. After centrifugation, the plasma 
was transferred into properly labeled eppen-
droff tubes and stored at a temperature of -
20 °C until analysis. OMP and its metabolites 
were extracted from the plasma using precip-
itation method and were analyzed using 
LCMS method. The mobile phase consisted 
of 0.1 % formic acid in acetonitrile: 0.1 % 
formic acid in water (40/60 v/v) using 
Hichrom RP18 (150 × 3.0 mm, 3 µm UK) as 
a stationary phase interfaced with a LTQ Or-
bit rap mass spectrometer. Pantoprazole was 
used as an internal standard (Ahmad et al., 
2015). 
The plasma concentration (mean ± SD) as 
a function of time curves for OMP, 5-OH-
OMP and OMP-S were plotted when OMP 
was administered alone or in combination 
with CLOP as shown in Figure 1.  
 
Table 1: The study design of drug-drug interaction of omeprazole with clopidogrel in healthy human 
volunteers 
Treatment sequence Group I (n = 6) Group II (n = 6) 
Sequence 1 OMP 40 mg alone OMP 40 mg+ CLOP 150 mg 
Wash out period of 14 days 
Sequence 2 OMP 40 mg + CLOP 150 mg OMP 40 mg alone 
 
 
 
Figure 1: Mean ± SD plasma concentration (µg/ml) of OMP, 5-OH-OMP and OMP as a function of 
time in EM (n = 8) and PM (n = 4), when OMP (40 mg) administered alone and in combination with 
CLOP (150 mg). 
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Various PK parameters were calculated 
using the PK Solutions software. The maxi-
mum plasma concentration (Cmax) and time to 
reach Cmax (tmax) were determined from 
plasma concentration-time profile of OMP, 5-
OH-OMP and OMP-S. The AUC0-∞ was de-
termined by trapezoidal rule. The elimination 
half life was determined by using first-order 
equation, i.e., 
ݐଵ/ଶ ൌ ଴.଺ଽଷ௞ . 
The apparent oral clearance (CL/F) was deter-
mined by using equation, Dose/AUC0-∞. The 
pharmacokinetic data was interpreted statisti-
cally using SPSS software (version 16.0; 
SPSS, Inc, Chicago, IL). A paired t-test was 
performed for the comparison of pharmacoki-
netic parameters of OMP, 5-OH-OMP and 
OMP-S when OMP was administered alone 
and in combination with CLOP in both EM 
and PM. P < 0.05 was considered statistically 
significant. 
 
RESULTS 
Volunteers were divided into EM and PM 
by drug metabolite ratio (Shilbayeh and 
Tutunji, 2006), i.e., [AUC]OMP/5-OH-OMP for 
EM was 1.94 ±0.602 while for PM it was 9.84 
± 4.543. [AUC]OMP/OMP-S for EM and PM was 
13.64 ± 2.711 and 9.85 ± 4.98, respectively. 
The pharmacokinetic parameters for both 
OMP, 5-OH-OMP and OMP-S alone and in 
combination with CLOP in EM and PM are 
shown in Table 2 and Table 3, respectively. 
 
 
Table 2: Pharmacokinetic parameters of omeprazole, 5-hydroxyomeprazole and omeprazole sulfone in 
extensive metabolizers when the subjects received omeprazole (40 mg) alone and in combination with 
clopidogrel(150 mg) 
Parameter  OMP-alone OMP+CLOP % increase p-value 
OMP 
Cmax (µg/ml) 0.89 ± 0.083 1.09 ± 0.146 8.25% ± 3.3 % 0.061 
Tmax (hr) 2.8 ± 0.178 2.9 ± 0.228 0.043% ± 0.0204% 0.465 
AUC0-∞ (µg-hr/ml) 4.04 ± 0.282 4.901 ± 0.620 9.33% ± 5.13% 0.095 
Cl (ml/hr/kg) 137.833 ± 23.395 116.667 ± 21.36 -15.42% ± 4.92%** 0.272 
E Half-life (hr) 1.05 ± 0.187 1.134 ± 0.185 6.31% ± 4.31% 0.800 
5-OH-OMP 
Cmax (µg/ml) 0.562 ± 0.053 0.401 ± 0.035 -16.23% ± 5.8%** 0.045* 
Tmax (hr) 2.723 ± 0.394 2.49 ± 0.281 -8.23 ± 4.3** 0.15 
AUC0-∞ (µg-hr/ml) 2.203 ± 0.619 1.615 ± 0.401 -14.22% ± 2.80%** 0.07 
E Half-life (hr) 1.24 ± 0.129 1.097 ± 0.106 -8.30% ± 6.1%** 0.102 
OMP-S 
Cmax (µg/ml) 0.175 ± 0.024 0.198 ± 0.026 8.01% ± 2.0% 0.04* 
Tmax (hr) 2.723 ± 0.278 2.652 ± 0.255 -2.5% ± 1.18%**  
AUC0-∞ (µg-hr/ml) 0.535 ± 0.058 0.612 ± 0.07 5.01% ± 1.57% 0.06 
E Half-life (hr) 2.367 ± 0.472 2.479 ± 0.496 3.81% ± 1.70% 0.371 
*P < 0.05, **- sign shows % decrease 
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Table 3: Pharmacokinetic parameters of omeprazole, 5-hydroxyomeprazole and omeprazole sulfone in 
poor metabolizers when the subjects received omeprazole (40 mg) alone and in combination with 
clopidogrel (150 mg). 
Parameter OMP-alone OMP+CLOP % increase p-value 
OMP 
Cmax (µg/ml) 1.413 ± 0.146 1.634 ± 0.116 5.46% ± 2.08% 0.08 
Tmax (hr) 2.992 ± 0.411 2.981 ± 0.414 -0.78% ± 0.32%* 0.53 
AUC0-∞ (µg-hr/ml) 8.823 ± 0.778 9.067 ± 0.861 4.11% ± 1.68% 0.13 
Cl (ml/hr/kg) 58.641 ± 8.66 52.947 ± 7.51 -9.6% ± 1.72* 0.15 
E Half-life (hr) 1.583 ± 0.058 1.507 ± 0.049 -4.73% ± 3.06* 0.51 
5-OH-OMP 
Cmax (µg/ml) 0.407 ± 0.046 0.373 ± 0.032 -4.9% ± 3.61%* 0.07 
Tmax (hr) 2.988 ± 0.311 3.138 ± 0.251 5.20% ± 4.0% 0.8 
AUC0-∞ (µg-hr/ml) 1.607 ± 0.126 1.566 ± 0.09 -1.73% ± 2.38%* 0.11 
E Half-life (hr) 2.588 ± 0.111 2.828 ± 0.188 2.83% ± 0.19% 0.6 
OMP-S 
Cmax (µg/ml) 0.444 ± 0.053 0.431 ± 0.056 -3.83% ± 1.53%* 0.1 
Tmax (hr) 3.063 ± 0.17 2.995 ± 0.077 -3.28% ±  0.60%* 0.3 
AUC0-∞ (µg-hr/ml) 1.495 ± 0.118 1.518 ± 0.102 2.32% ± 2.9% 0.13 
E Half-life (hr) 3.338 ± 0.438 3.141 ± 0.44 -6.08% ± 0.96%* 0.4 
*- sign shows % decrease 
 
Plots for plasma concentration as a func-
tion of time were constructed for OMP, 5-
OH-OMP and OMP-S when the subjects re-
ceived OMP alone or in combination with 
CLOP in EM and PM as shown in Figure 1. 
The changes in all the parameters of OMP 
and its metabolites were insignificant after ad-
ministration of CLOP except the Cmax of 5-
OH-OMP and OMP-S in EM which was sig-
nificantly altered (P < 0.05). The AUC0-∞ and 
Cmax of OMP were increased in both EM and 
PM after concomitant administration of 
CLOP but the percent increase is much more 
in EM than PM. The AUC0-∞ and Cmax of 5-
OH-OMP were decreased in both EM and PM 
after co-administration of CLOP with OMP. 
An increase in the Cmax and AUC0-∞in the 
other metabolite formed through CYP3A4 
(OMP-S) was observed both in EM and PM. 
 
DISCUSSION 
In literature, only one report was found 
that supported the interaction between OMP 
and CLOP. This previously reported study il-
lustrates that the interaction between OMP 
and CLOP is based on the inhibition of 
CYP2C19 by CLOP (Chen et al., 2009). 
Changes in pharmacokinetic parameters of 
OMP and its metabolites were observed in the 
present study for both EM and PM. The in-
crease in the Cmax (8.25% ± 3.3 %) and  
AUC0-∞ (9.33% ± 5.13%) of OMP after con-
comitant administration of CLOP in EM may 
be due to the inhibition of CYP2C19, which 
resulted in decreased formation of 5-OH-
OMP. CLOP is also a substrate of CYP3A4 
but there is no study to date that suggests 
whether it is inducer or inhibitor of CYP3A4. 
Drugs that are substrates of CYP450, may 
also act as inhibitor or inducer of that particu-
lar CYP isoform. For example, carbamaze-
pine is a substrate as well as inducer of 
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CYP3A4, similarly clarithromycin is a sub-
strate as well as inhibitor of CYP3A4 (Zhou, 
2008). Though OMP is not mainly metabo-
lized by CYP3A4 but a slight increase in 
AUC0-∞ and Cmax of OMP-S after concomi-
tant in EM may be due to the induction of 
CYP3A4 by CLOP. The other possible reason 
for increase of OMP-S may be the CLOP in-
duced inhibition of CYP2C19 dependent hy-
droxylation, and in turn OMP is predomi-
nantly metabolized by CYP3A4. 
Previously reported studies of OMP phar-
macokinetics suggest that OMP concentration 
(Cmax and AUC0-∞) was greater in PM as com-
pared to EM. On the other hand, 5-OH-OMP 
concentration was high in EM and low in PM, 
and OMP-S concentration was reported to be 
high in PM as compared to EM, suggesting 
that sulfoxidation is the major metabolic path-
way in PM (Uno et al., 2007; Yin et al., 2004). 
In present study, the OMP concentration was 
increased in PM and 5-OH-OMP concentra-
tion was decreased after co-administration of 
CLOP while OMP-S was increased in PM af-
ter concomitant administration of OMP with 
CLOP. The decrease in hydroxylation or in-
crease in sulfoxidation of OMP in PM was in-
significant and the changes in the pharmaco-
kinetic parameters were much smaller by con-
sidering the percent decrease or increase in 
their respective concentration as shown in ta-
ble 3. CLOP absorption and its active metab-
olite formation are decreased by the P-glyco-
protein efflux (Taubert et al., 2006). Similarly 
OMP is a substrate as well as inhibitor of P-
glycoprotein (Pauli-Magnus et al., 2001). The 
other possible reason for the increase of OMP 
concentration may be inhibition of this efflux 
pump by CLOP but this is a weak mechanistic 
approach as previously it has been reported 
that OMP pharmacokinetics were not altered 
by fexofenadine, a P-glycoprotein inhibi-
tor/substrate (Takahata et al., 2004). 
In conclusion, CLOP inhibits hydroxyla-
tion of OMP to a greater extent in EM than in 
PM, leading to higher OMP Cmax and AUC0-
∞. Furthermore, the sulfoxidation of OMP is 
induced either by induction of CYP3A4 or by 
inhibition of CYP2C19 as result OMP is me-
tabolized to a greater extent by CYP3A4. It is 
suggested that OMP and CLOP should not be 
administered concomitantly. 
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